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Objective: Zolpidem is a non-benzodiazepine hypnotic drug for treatment of insomnia. It has been introduced as a
lower potential agent for dependency and abusive effects.
Case summary: In this study, the reported case was a 62 years old female patient suffering simultaneously with
Major Depressive Disorder and Opium Dependency. After abrupt discontinuation of zolpidem, 570 mg per day, she
exhibited severe withdrawal symptoms, led her to be admitted to emergency department.
Conclusions: Zolpidem has a potency to be abused with high risk of dependency and withdrawal syndromes
particularly among elderly patients with comorbid anxiety/depressive symptoms/disorders.
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A new generation of nonbenzodiazepine hypnotics called
“Zdrugs” was introduced to clinical practice in 1980s.
These drugs have fast onset of hypnotic effect and short
acting duration [1].
Zolpidem (Ambien) is an imidazopyridin which is con-
sidered as nonbenzodiazepine regarding having no diaze-
pine binding activity. However, in therapeutic dosage it
affects type 1 benzodiazepine receptors selectively [2].
Zolpidem is one of the most prescribed medications to
treat insomnia in elderly patients. Although some cases
of abuse and dependency on zolpidem have been re-
ported in the last decades, few cases have been identified
in elderly patients with the same problem [3].
In a literature review carried out by us, only 4 reports
of zolpidem dependency and withdrawal symptoms have
been found in elderly patients. A summary of these re-
ports were presented in Table 1 [3-6].
This report presents a complicated 62 years female pa-
tient with dependency and withdrawal symptoms after
abrupt discontinuation of 570 mg/daily of zolpidem.* Correspondence: malakoutik@gmail.com
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The case was a female patient, aged 62, married, illiterate
and housewife who were admitted to Emergency Depart-
ment (ED) of Rasoul Akram hospital in the June of 2013.
After abrupt discontinuation of zolpidem, she presented
to ED with restlessness; sever agitation, crying, severe anx-
iety, impatience, loss of energy, insomnia, irritability, ver-
bal aggression, distraction, increased appetite, physical
symptoms such as headaches and lightheadedness, severe
shivering, and increased craving for higher dosage of
opium. Urging and pressure of her close relatives was the
main reason to quit the zolpidem at once. Further evalu-
ation revealed that she had been suffering from Major
Depressive Disorder (MDD) since 5 years ago that had
never been noticed and managed psychiatrically. Approxi-
mately since two years before this hospitalization, the pa-
tient had started taking 10 mg of zolpidem prescribed by a
general physician for her insomnia. After several months
of consumption, she herself titrated of dosage for her re-
sistant insomnia up to 570 mg per day in divided dosage.
According to her report, in addition of her insomnia, de-
pressive and anxiety comorbid symptoms were improved
by every step up the zolpidem dosage.
She used to take opium for one year and quitted for
the next four years. However, to alleviate her discomfortMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Studies reviewed for dependency and withdrawal syndromes of zolpidem in elderly patients
No. Authors Year of publication Patient’s age Gender Daily dose (mg) Period (month)+ Psychiatric diagnosis++
1 Fernandez et al. 2013 72 Female 300 Over 8 Not mentioned
2 Styliani S et al. 2009 78 Male 300 Not mentioned Not mentioned
3 Leslie N et al. 2001 67 Female 100 18 Drug abuse+ symptoms of
depression and anxiety
4 Liappas I.A et al. 2001 80 Female 100 Not mentioned Without past psychiatric history
+Period (month): duration of zolpidem abuse/dependency before hospitalization.
++Psychiatric diagnosis: included past or current psychiatric diagnosis as comorbid disorder with zolpidem abuse/dependency.
Pourshams and Malakouti DARU Journal of Pharmaceutical Sciences 2014, 22:54 Page 2 of 3
http://www.darujps.com/content/22/1/54from psychological symptoms, she had started to take it
orally again during the last year.
As explained by the patient, opium and zolpidem had
been consumed simultaneously for its relaxing and eu-
phoric effects.
Although the patient had a history of MDD, neverthe-
less, the above mentioned symptoms were beyond the cri-
terion which could be attributed to recurrent of MDD
diagnosis, according to diagnostic criteria. The onset of
symptoms in one month of quitting abusive substance,
make the “withdrawal” diagnosis eligible. Thus the patient
was formulated with diagnosis of: 1.Zolpidem withdrawal
syndrome, 2. MDD, 3. Opium dependency according to
Diagnostic and Statistical Manual of Mental Disorders 4th
edition- Text Revision (DSM- IV-TR).
Complete Blood Count (CBC), biochemistry test, thyroid
test, Magnetic Resonance Imaging (MRI) as well as electro-
cardiography, echocardiography and urine test were in nor-
mal range. Urine screening test was positive for opium.
Treatment
The patient has been managed by 1) Gabapentin
(900 mg in divided doses per day), sertraline (200 mg per
day) and trazodone (100 mg at bedtime). Although both
of them will increase the serotonin level, however it
helped to overcome the insomnia of the patient without
any side effect of serotonergic syndrome. 2) Patient’s oral
consumption of opium was stopped and replaced by
methadone, the dosage of the methadone gradually ta-
pered up to 40 mg per day. Close monitoring did not show
any cardiac side effect of methadone and trazodone com-
bination. After three weeks of hospitalization, she has
been discharged from hospital in good condition. She was
on the same medication two months after discharge and
her mental and physical conditions were stable without
any craving for both opium and zolpidem.
Conclusion
Depressive disorder and insomnia is one the most prevalent
mental disorders among the elderly [7]. A few studies sug-
gested that the short-term use of benzodiazepine receptor
agonists may be safe in old population [8,9]. However, seda-
tive hypnotics are considered as potentially high-risk drugs
in the elderly (aged ≥ 65 years) by the AGS 2012 BeersCriteria Update Expert Panel [10]. Recent publications indi-
cated that benzodiazepine receptor agonists increase the
risk of cognitive impairment, delirium, falling and motor
vehicle accident [10]. A meta-analysis showed that an un-
pleasant event is more than twice as likely as improved
quality of sleep [11].
Being concerned of dependency to benzodiazepine and
its detrimental side effects such as forgetfulness in eld-
erly, may encourage the general physicians prescribe zol-
pidem frequently without enough Psychoeducation of
clients and on the other hand, the patients may take and
overdose zolpidem for insomnia on their own [12].
Zolpidem is a nonbenzodiazepine hypnotic with a short
half-life of 1.5 to 3.2 hours [1]. Due to its selective effect on
type 1 benzodiazepine receptors, it has hypnotic and anxio-
lytic action without muscle relaxant and anticonvulsant
effect. Lack of effects on benzodiazepine-3 receptors, it ap-
pears to result in a lower incidence of withdrawal and re-
bound symptoms, despite the fact that these may occur at
higher doses particularly with long-term prescription [2].
Zolpidem acts in therapeutic doses selectively on recep-
tors with α sub-unit. In contrast to benzodiazepines; it has
no effect on other sub-units of such as sub-unit in amyg-
dale whose activity by benzodiazepines has anti-anxiety ef-
fects [4]. Zolpidem acts in less selective manner in doses
higher than therapeutic doses which can be of greater
anxiolytic effect by affecting receptors with α2 sub-units.
As the elderly are more likely to show mixed signs of anx-
iety and depression, the antianxiety effect of the medicine
increases the risk of its overdose in the elderly and be-
comes more noteworthy when insomnia is concurrent
with psychiatric disorders. Patients with psychiatric disor-
ders often exhibit symptoms of insomnia and thus a great
tendency toward abuse of alcohol, drugs, and hypnotics as
their coping strategy or self-medication behavior [2,13]. It
has been shown in clinical practice that although zolpidem
is a safe drug, there is some risk of abuse and dependency
usually related to long–term use of high doses especially
in patients with previous history of substance abuse or
psychiatric disorders such as depression and insomnia
which can bring about the abuse and dependency on this
medicine [3]. Self-escalation of the zolpidem dose can re-
sult in tolerance to the hypnotic and sedative effects of
zolpidem. Low renal clearance in elderly may increase the
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zolpidem [14]. The elderly people seem to have a higher
risk for zolpidem abuse or dependency, not only for its
high frequency of sleep and mood disorders, but also for
the reduction of the zolpidem clearance. In elderly popula-
tion, peak plasma concentrations are 50% higher, which
means that in elderly subjects even with lower doses of
zolpidem, the phenomena of abuse or dependence could
be envisaged [3].
Symptoms of sweating, tachycardia, tachypnea, tremors,
and severe anxiety have been reported upon discontinu-
ation of zolpidem. Discontinuation syndrome symptoms
also include fatigue, nausea, flushing, panic attacks, ab-
dominal discomfort, uncontrolled crying, emesis, delirium,
and even seizure, some of which were observed in our
case study [15].
The recommended dose is 5 mg at night in male and fe-
male elderly patients [10]. It is advised that secondary
causes of insomnia such as psychiatric and physical condi-
tions should be treated in elderly patients and more atten-
tion should be paid to nonpharmacological treatments
such as improvement of sleep hygiene [16,17].
Although it is generally believed that zolpidem is a safe
medication to use for insomnia; however it could have
deleterious side effect for the elderly particularly with
depressive disorder and history of substance abuse.
Consent
Written informed consent was obtained from the patient
for the publication of this report.
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